Data are provided by many contributors through the the WHO Clinical data platform and are not necessarily representative. To become a contributor, please see the terms of use and register here.

Total cases

94

Confirmed cases

53

Total PLWH

15

Women

42.6%

Children below 5

14.9%

Total deaths

1

The map below is just a proof of concept. Can be adjusted once/if we have data at the regional level.

Geospatial distribution
Cases reported
Mirror plots
Chronic conditions
Variable Sample size Prevalence pct Frequency
HIV (Human Immunodeficiency Virus) 94 16.0% 15 / 94
Hypertension 94 4.3% 4 / 94
Current new STI (Sexually Transmitted Infection) diagnosis? 94 3.2% 3 / 94
Syphilis 3 100.0% 3 / 3
Current alcohol use disorder 94 1.1% 1 / 94
Immunosuppressive condition 94 1.1% 1 / 94
Chronic heart disease 94 0.0% 0 / 94
Chronic lung disease 94 0.0% 0 / 94
Chronic kidney disease 94 0.0% 0 / 94
Chronic liver disease 94 0.0% 0 / 94
Chronic neurologic condition 94 0.0% 0 / 94
Previous COVID-19 infection 94 0.0% 0 / 94
Diabetes 94 0.0% 0 / 94
Currently smokes tobacco 94 0.0% 0 / 94
Skin Conditions 94 0.0% 0 / 94
Tuberculosis (previous) 94 0.0% 0 / 94
Tuberculosis (active) 94 0.0% 0 / 94
Asplenia 94 0.0% 0 / 94
Cancer 94 0.0% 0 / 94
N. gonorrhoeae 3 0.0% 0 / 3
HSV 3 0.0% 0 / 3
Chlamydia trachomatis 3 0.0% 0 / 3
HPV 3 0.0% 0 / 3
AIDS - defining illness 14 0.0% 0 / 14

Source: WHO
Complications
Variable Sample size Prevalence pct Frequency
Cellulitis 90 26.7% 24 / 90
Bacteraemia 90 12.2% 11 / 90
Abscess 90 5.6% 5 / 90
Anaemia 90 4.4% 4 / 90
Sepsis 90 3.3% 3 / 90
Viral Pneumonia / Pneumonitis 90 3.3% 3 / 90
Bacterial Pneumonia 90 3.3% 3 / 90
Ocular Complications 90 2.2% 2 / 90
Shock 90 1.1% 1 / 90
Encephalitis / Meningitis 90 1.1% 1 / 90
Bleeding Disorder 90 1.1% 1 / 90
Cardiac Arrest 90 1.1% 1 / 90
Cardiac Arrhythmia 90 1.1% 1 / 90
Cardiomyopathy 90 1.1% 1 / 90
Myocarditis / Pericarditis 90 1.1% 1 / 90
Acute Respiratory Distress Syndrome (Ards) 90 1.1% 1 / 90
Urinary Retention 90 1.1% 1 / 90
Necrotizing Infection 90 1.1% 1 / 90
Seizure 90 0.0% 0 / 90
Stroke / Cerebrovascular Accident 90 0.0% 0 / 90
Guillain-Barré Syndrome 90 0.0% 0 / 90
Acute Renal Injury / Acute Renal Failure 90 0.0% 0 / 90
Pancreatitis 90 0.0% 0 / 90
Liver Dysfunction 90 0.0% 0 / 90
Proctitis 90 0.0% 0 / 90
Rectal Urgency 90 0.0% 0 / 90
Rectal Pain 90 0.0% 0 / 90

Source: WHO
Body map of lesions at admission
Prevalence of lesions at admission
Variable Sample size Prevalence pct Frequency
Upper limb 93 83.9% 78/93
Head and neck 93 80.6% 75/93
Chest and abdomen 93 78.5% 73/93
Lower limb 93 77.4% 72/93
Back 93 75.3% 70/93
Genitals 93 49.5% 46/93
Mouth 92 23.9% 22/92

Source: WHO
Type of lesions
Variable Sample size Prevalence pct Frequency
Papule 94 77.7% 73/94
Macule 94 55.3% 52/94
Crusting of a mature lesion 94 38.3% 36/94
Small pustule 94 36.2% 34/94
Umbilicated pustule 94 33.0% 31/94
Ulcerated lesion 94 31.9% 30/94
Early vesicle 94 28.7% 27/94
Partially removed scab 94 18.1% 17/94

Source: WHO
Reported symptoms
Symptoms at admission
Variable Sample size Prevalence pct Frequency
Fever 93 84.9% 79 / 93
Pruritis/itching 93 66.7% 62 / 93
Headache 94 60.6% 57 / 94
Muscle pain or aching 94 53.2% 50 / 94
Fatigue or malaise 94 52.1% 49 / 94
Sore throat 94 41.5% 39 / 94
Swallowing problem 94 28.7% 27 / 94
Joint pain or aching 94 27.7% 26 / 94
Painful swallow 27 96.3% 26 / 27
Pain in mouth 94 25.5% 24 / 94
Urinary symptoms 94 22.3% 21 / 94
Pain with urination 21 100.0% 21 / 21
Psychologic disturbance 94 14.9% 14 / 94
Dizziness 94 11.7% 11 / 94
Difficult swallow 27 29.6% 8 / 27
Nausea 94 7.4% 7 / 94
Ocular symptoms (pain, redness, visual loss) 94 5.3% 5 / 94
Red eye(s) 5 100.0% 5 / 5
Vomiting 94 4.3% 4 / 94
Chest pain 94 4.3% 4 / 94
Decrease urine output 20 20.0% 4 / 20
Diarrhoea 94 3.2% 3 / 94
Eye pain 5 60.0% 3 / 5
Any rectal symptom 94 2.1% 2 / 94
Urethral discharge 21 9.5% 2 / 21
Rectal pain 2 100.0% 2 / 2
Other 5 20.0% 1 / 5
Proctitis 94 0.0% 0 / 94
Rectal discharge 2 0.0% 0 / 2
Rectal urgency/tenesmus 2 0.0% 0 / 2
Visual disturbance 5 0.0% 0 / 5
...with blood 4 0.0% 0 / 4

Source: WHO
Symptoms at discharge
Variable Sample size Prevalence pct Frequency
Pruritis/itching 89 3.4% 3 / 89
Sore throat 90 1.1% 1 / 90
Fever 90 0.0% 0 / 90
Muscle pain or aching 90 0.0% 0 / 90
Headache 90 0.0% 0 / 90
Ocular symptoms (pain, redness, visual loss) 90 0.0% 0 / 90
Fatigue or malaise 90 0.0% 0 / 90
Pain in mouth 90 0.0% 0 / 90
Nausea 90 0.0% 0 / 90
Vomiting 90 0.0% 0 / 90
Diarrhoea 90 0.0% 0 / 90
Any rectal symptom 90 0.0% 0 / 90
Swallowing problem 90 0.0% 0 / 90
Chest pain 90 0.0% 0 / 90
Joint pain or aching 90 0.0% 0 / 90
Proctitis 90 0.0% 0 / 90
Dizziness 90 0.0% 0 / 90
Psychologic disturbance 90 0.0% 0 / 90
Urinary symptoms 90 0.0% 0 / 90

Source: WHO
Variable

Person with HIV
N = 15

Person without HIV
N = 70

Unknown
N = 9

 p-value 1
age, Median (Q1, Q3) 9.50 (8.00, 12.00) 8.00 (5.00, 9.00) 9.00 (8.00, 10.00) 0.005
    Missing/Unknown 1 0 0
Sex at birth, n (%)


0.021
    Male 5 (33%) 45 (64%) 3 (33%)
    Female 9 (60%) 25 (36%) 6 (67%)
    Intersex 0 (0%) 0 (0%) 0 (0%)
    Unknown 1 (6.7%) 0 (0%) 0 (0%)
Race, n (%)


>0.9
    African/Black 14 (93%) 65 (93%) 9 (100%)
    Arab 0 (0%) 0 (0%) 0 (0%)
    Asian 0 (0%) 0 (0%) 0 (0%)
    Hispanic/Latino 0 (0%) 0 (0%) 0 (0%)
    Mixed Race 0 (0%) 0 (0%) 0 (0%)
    White 0 (0%) 0 (0%) 0 (0%)
    Unknown 1 (6.7%) 5 (7.1%) 0 (0%)
    Other 0 (0%) 0 (0%) 0 (0%)
health care worker, n (%)


0.4
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 14 (93%) 69 (99%) 9 (100%)
    Unknown 1 (6.7%) 1 (1.4%) 0 (0%)
Laboratory worker, n (%)


0.7
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 14 (93%) 67 (96%) 9 (100%)
    Unknown 1 (6.7%) 3 (4.3%) 0 (0%)
Sex worker, n (%)


<0.001
    Yes 7 (47%) 2 (2.9%) 1 (11%)
    No 7 (47%) 64 (91%) 8 (89%)
    Unknown 1 (6.7%) 4 (5.7%) 0 (0%)
currently pregnant or was pregnant in the last 6 weeks?, n (%)


>0.9
    Yes 0 (0%) 1 (4.0%) 0 (0%)
    No 9 (100%) 24 (96%) 6 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 6 45 3
Breastfeeding, n (%)



    Yes 0 (NA%) 0 (NA%) 0 (NA%)
    No 0 (NA%) 0 (NA%) 0 (NA%)
    Unknown 0 (NA%) 0 (NA%) 0 (NA%)
    Missing/Unknown 15 70 9
1

Kruskal-Wallis rank sum test; Fisher’s exact test
Variable

Person with HIV
N = 15

Person without HIV
N = 70

Unknown
N = 9

 p-value 1
ever hospitalized, n (%)


0.5
    Yes 10 (77%) 58 (84%) 8 (100%)
    No 3 (23%) 11 (16%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 1 1
Length of hospitalization, Median (Q1, Q3) 12 (5, 15) 7 (5, 12) 7 (5, 10) 0.2
    Missing/Unknown 5 12 1
Escalation of care, n (%)


0.054
    Yes 1 (10%) 0 (0%) 1 (13%)
    No 9 (90%) 58 (100%) 7 (88%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 5 12 1
supplemental oxygen, n (%)


0.038
    Yes 1 (10%) 0 (0%) 0 (0%)
    No 9 (90%) 58 (100%) 7 (88%)
    Unknown 0 (0%) 0 (0%) 1 (13%)
    Missing/Unknown 5 12 1
receive nasogastric fluids, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 13 (100%) 69 (100%) 8 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 1 1
receive IV fluids during course monkeypox infection, n (%)


0.021
    Yes 2 (15%) 2 (2.9%) 2 (25%)
    No 11 (85%) 67 (97%) 6 (75%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 1 1
receive analgesia for pain management, n (%)


0.002
    Yes 10 (77%) 22 (32%) 6 (75%)
    No 3 (23%) 47 (68%) 2 (25%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 1 1
receive antibiotics during course monkeypox infection, n (%)


>0.9
    Yes 12 (92%) 62 (90%) 8 (100%)
    No 1 (7.7%) 7 (10%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 1 1
receive antifungals during course monkeypox infection, n (%)


0.2
    Yes 1 (7.7%) 0 (0%) 0 (0%)
    No 12 (92%) 69 (100%) 8 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 1 1
experimental antiviral during course monkeypox infection, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 13 (100%) 69 (100%) 8 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 1 1
1

Fisher’s exact test; Kruskal-Wallis rank sum test
Variable

Person with HIV
N = 15

Person without HIV
N = 70

Unknown
N = 9

 p-value 1
History of tetanus vaccination, n (%)


0.2
    Yes 0 (0%) 7 (10%) 2 (22%)
    No 4 (27%) 27 (39%) 4 (44%)
    Unknown 11 (73%) 36 (51%) 3 (33%)
History of smallpox vaccination before 1980, n (%)


0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 12 (80%) 59 (84%) 8 (89%)
    Unknown 3 (20%) 11 (16%) 1 (11%)
History of smallpox or monkeypox vaccination in past year, n (%)


0.8
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 14 (93%) 65 (93%) 8 (89%)
    Unknown 1 (6.7%) 5 (7.1%) 1 (11%)
Number of vaccines received, Median (Q1, Q3) NA (NA, NA) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 15 70 9
1

Fisher’s exact test
Variable

Person with HIV
N = 15

Person without HIV
N = 70

Unknown
N = 9

 p-value 1
New diagnosis of HIV, n (%)


0.11
    Yes 0 (0%) 1 (1.4%) 1 (13%)
    No 12 (100%) 67 (97%) 6 (75%)
    Unknown 0 (0%) 1 (1.4%) 1 (13%)
    Missing/Unknown 3 1 1
Current new STI (Sexually Transmitted Infection) diagnosis, n (%)



    Yes 0 (0%) 0 (NA%) 0 (NA%)
    No 3 (100%) 0 (NA%) 0 (NA%)
    Unknown 0 (0%) 0 (NA%) 0 (NA%)
    Missing/Unknown 12 70 9
Immunosuppressive condition, n (%)


0.002
    Yes 1 (6.7%) 0 (0%) 0 (0%)
    No 14 (93%) 70 (100%) 7 (78%)
    Unknown 0 (0%) 0 (0%) 2 (22%)
Most recent CD4, Median (Q1, Q3) 98 (98, 98) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 1 70 9
Viral load, n (%)



    Detectable 0 (0%) 0 (NA%) 0 (NA%)
    Undetectable 3 (21%) 0 (NA%) 0 (NA%)
    Unknown 11 (79%) 0 (NA%) 0 (NA%)
    Missing/Unknown 1 70 9
AIDS - defining illness, n (%)



    Yes 0 (0%) 0 (NA%) 0 (NA%)
    No 14 (100%) 0 (NA%) 0 (NA%)
    Unknown 0 (0%) 0 (NA%) 0 (NA%)
    Missing/Unknown 1 70 9
1

Fisher’s exact test
Skin lesions by HIV status
Complications by HIV status
Variable

Confirmed case
N = 53

Not confirmed
N = 36

 p-value 1
HIV status, n (%)

<0.001
    Person with HIV 12 (23%) 1 (2.8%)
    Person without HIV 33 (62%) 35 (97%)
    Unknown 8 (15%) 0 (0%)
age, Median (Q1, Q3) 8.00 (7.00, 10.00) 7.00 (5.00, 8.50) 0.017
Sex at birth, n (%)

0.2
    Male 27 (51%) 24 (67%)
    Female 26 (49%) 12 (33%)
    Intersex 0 (0%) 0 (0%)
    Unknown 0 (0%) 0 (0%)
Race, n (%)

>0.9
    African/Black 50 (94%) 34 (94%)
    Arab 0 (0%) 0 (0%)
    Asian 0 (0%) 0 (0%)
    Hispanic/Latino 0 (0%) 0 (0%)
    Mixed Race 0 (0%) 0 (0%)
    White 0 (0%) 0 (0%)
    Unknown 3 (5.7%) 2 (5.6%)
    Other 0 (0%) 0 (0%)
health care worker, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 52 (98%) 36 (100%)
    Unknown 1 (1.9%) 0 (0%)
Laboratory worker, n (%)

0.6
    Yes 0 (0%) 0 (0%)
    No 52 (98%) 34 (94%)
    Unknown 1 (1.9%) 2 (5.6%)
Sex worker, n (%)

0.015
    Yes 9 (17%) 0 (0%)
    No 42 (79%) 34 (94%)
    Unknown 2 (3.8%) 2 (5.6%)
currently pregnant or was pregnant in the last 6 weeks?, n (%)

0.3
    Yes 0 (0%) 1 (8.3%)
    No 26 (100%) 11 (92%)
    Unknown 0 (0%) 0 (0%)
    Missing/Unknown 27 24
Breastfeeding, n (%)


    Yes 0 (NA%) 0 (NA%)
    No 0 (NA%) 0 (NA%)
    Unknown 0 (NA%) 0 (NA%)
    Missing/Unknown 53 36
1

Fisher’s exact test; Wilcoxon rank sum test
Variable

Confirmed case
N = 53

Not confirmed
N = 36

 p-value 1
HIV status, n (%)

<0.001
    Person with HIV 12 (23%) 1 (2.8%)
    Person without HIV 33 (62%) 35 (97%)
    Unknown 8 (15%) 0 (0%)
ever hospitalized, n (%)

0.2
    Yes 47 (89%) 28 (78%)
    No 6 (11%) 8 (22%)
    Unknown 0 (0%) 0 (0%)
Length of hospitalization, Median (Q1, Q3) 9 (5, 14) 5 (4, 10) 0.013
    Missing/Unknown 6 8
Escalation of care, n (%)

>0.9
    Yes 1 (2.1%) 1 (3.6%)
    No 46 (98%) 27 (96%)
    Unknown 0 (0%) 0 (0%)
    Missing/Unknown 6 8
supplemental oxygen, n (%)

0.6
    Yes 0 (0%) 1 (3.6%)
    No 46 (98%) 27 (96%)
    Unknown 1 (2.1%) 0 (0%)
    Missing/Unknown 6 8
receive nasogastric fluids, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 53 (100%) 36 (100%)
    Unknown 0 (0%) 0 (0%)
receive IV fluids during course monkeypox infection, n (%)

0.4
    Yes 5 (9.4%) 1 (2.8%)
    No 48 (91%) 35 (97%)
    Unknown 0 (0%) 0 (0%)
receive analgesia for pain management, n (%)

0.002
    Yes 30 (57%) 8 (22%)
    No 23 (43%) 28 (78%)
    Unknown 0 (0%) 0 (0%)
receive antibiotics during course monkeypox infection, n (%)

>0.9
    Yes 49 (92%) 33 (92%)
    No 4 (7.5%) 3 (8.3%)
    Unknown 0 (0%) 0 (0%)
receive antifungals during course monkeypox infection, n (%)

>0.9
    Yes 1 (1.9%) 0 (0%)
    No 52 (98%) 36 (100%)
    Unknown 0 (0%) 0 (0%)
experimental antiviral during course monkeypox infection, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 53 (100%) 36 (100%)
    Unknown 0 (0%) 0 (0%)
1

Fisher’s exact test; Wilcoxon rank sum test
Variable

Confirmed case
N = 53

Not confirmed
N = 36

 p-value 1
HIV status, n (%)

<0.001
    Person with HIV 12 (23%) 1 (2.8%)
    Person without HIV 33 (62%) 35 (97%)
    Unknown 8 (15%) 0 (0%)
History of tetanus vaccination, n (%)

0.6
    Yes 4 (7.5%) 5 (14%)
    No 22 (42%) 12 (33%)
    Unknown 27 (51%) 19 (53%)
History of smallpox vaccination before 1980, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 45 (85%) 31 (86%)
    Unknown 8 (15%) 5 (14%)
History of smallpox or monkeypox vaccination in past year, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 49 (92%) 34 (94%)
    Unknown 4 (7.5%) 2 (5.6%)
Number of vaccines received, Median (Q1, Q3) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 53 36
1

Fisher’s exact test
Variable

Confirmed case
N = 53

Not confirmed
N = 36

 p-value 1
HIV status, n (%)

<0.001
    Person with HIV 12 (23%) 1 (2.8%)
    Person without HIV 33 (62%) 35 (97%)
    Unknown 8 (15%) 0 (0%)
New diagnosis of HIV, n (%)

0.8
    Yes 2 (3.8%) 0 (0%)
    No 49 (94%) 35 (97%)
    Unknown 1 (1.9%) 1 (2.8%)
    Missing/Unknown 1 0
Current new STI (Sexually Transmitted Infection) diagnosis, n (%)


    Yes 0 (0%) 0 (NA%)
    No 3 (100%) 0 (NA%)
    Unknown 0 (0%) 0 (NA%)
    Missing/Unknown 50 36
Immunosuppressive condition, n (%)

0.5
    Yes 0 (0%) 0 (0%)
    No 51 (96%) 36 (100%)
    Unknown 2 (3.8%) 0 (0%)
Most recent CD4, Median (Q1, Q3) 98 (98, 98) 98 (98, 98) 0.8
    Missing/Unknown 41 35
Viral load, n (%)

>0.9
    Detectable 0 (0%) 0 (0%)
    Undetectable 3 (25%) 0 (0%)
    Unknown 9 (75%) 1 (100%)
    Missing/Unknown 41 35
AIDS - defining illness, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 12 (100%) 1 (100%)
    Unknown 0 (0%) 0 (0%)
    Missing/Unknown 41 35
1

Fisher’s exact test; Wilcoxon rank sum test
Skin lesions by mpox status
Complications
Exposure distribution
Variable Sample size Prevalence pct Frequency
Sexually active within ≤ 21 days prior to symptom onset? 94 43.6% 41/94
Number of heterosexual partners in the last three months 40 72.5% 29/40
Any known link to probable or confirmed case of monkeypox within ≤ 21 days prior to symptom onset? 94 11.7% 11/94
International travel within ≤ 21 days prior to symptom onset? 94 4.3% 4/94
Contact with possible animal source within ≤ 21 days prior to symptom onset? 94 0.0% 0/94
Did the patient receive experimental antiviral during course monkeypox infection? 90 0.0% 0/90

Source: WHO
Variable N = 94
Mpox clade known:, n (%)
    Yes 0 (0%)
    No 90 (100%)
    Unknown 0 (0%)
    Missing/Unknown 4
Mpox clade, n (%)
    Ia 0 (NA%)
    Ib 0 (NA%)
    IIa 0 (NA%)
    IIb 0 (NA%)
    Missing/Unknown 94
Monkeypox PCR, n (%)
    Yes 89 (99%)
    No 1 (1.1%)
    Unknown 0 (0%)
    Missing/Unknown 4
Monkeypox Result, n (%)
    Positive 53 (60%)
    Negative 34 (38%)
    Indeterminate 0 (0%)
    Unknown 2 (2.2%)
    Missing/Unknown 5
Monkeypox viral culture, n (%)
    Yes 0 (0%)
    No 90 (100%)
    Unknown 0 (0%)
    Missing/Unknown 4
Monkeypox viral culture Result, n (%)
    Positive 0 (NA%)
    Negative 0 (NA%)
    Indeterminate 0 (NA%)
    Unknown 0 (NA%)
    Missing/Unknown 94
Variable N = 94
Orthopoxvirus PCR, n (%)
    Yes 0 (0%)
    No 90 (100%)
    Unknown 0 (0%)
    Missing/Unknown 4
Orthopoxvirus Result, n (%)
    Positive 0 (NA%)
    Negative 0 (NA%)
    Indeterminate 0 (NA%)
    Unknown 0 (NA%)
    Missing/Unknown 94
Variable N = 94
Malaria result, n (%)
    Positive 0 (0%)
    Negative 5 (100%)
    Indeterminate 0 (0%)
    Unknown 0 (0%)
    Missing/Unknown 89
Syphilis result, n (%)
    Positive 1 (50%)
    Negative 1 (50%)
    Indeterminate 0 (0%)
    Unknown 0 (0%)
    Missing/Unknown 92
Variable

Baseline visit
N = 94
Hemoglobin, Median (Q1, Q3) 12.80 (11.10, 15.30)
WCC total, Median (Q1, Q3) 6.9 (6.4, 11.1)
Platelets, Median (Q1, Q3) 254 (156, 319)
PT, Median (Q1, Q3) NA (NA, NA)
APTT, Median (Q1, Q3) NA (NA, NA)
Total Bilirubin, Median (Q1, Q3) NA (NA, NA)
ALT, Median (Q1, Q3) NA (NA, NA)
AST, Median (Q1, Q3) NA (NA, NA)
Na+, Median (Q1, Q3) NA (NA, NA)
K+, Median (Q1, Q3) NA (NA, NA)
Urea/BUN, Median (Q1, Q3) NA (NA, NA)
Creatinine, Median (Q1, Q3) NA (NA, NA)
Glucose, Median (Q1, Q3) NA (NA, NA)
Lactate, Median (Q1, Q3) NA (NA, NA)
CRP, Median (Q1, Q3) NA (NA, NA)
Creatine kinase, Median (Q1, Q3) NA (NA, NA)
Variable

During infection management
N = 200
Hemoglobin, Median (Q1, Q3) 12.60 (11.10, 15.00)
WCC total, Median (Q1, Q3) 7.2 (6.2, 9.5)
Platelets, Median (Q1, Q3) 266 (167, 364)
PT, Median (Q1, Q3) NA (NA, NA)
APTT, Median (Q1, Q3) NA (NA, NA)
Total Bilirubin, Median (Q1, Q3) NA (NA, NA)
ALT, Median (Q1, Q3) 22 (22, 22)
AST, Median (Q1, Q3) 34 (34, 34)
Na+, Median (Q1, Q3) 134 (134, 134)
K+, Median (Q1, Q3) 4.1600 (4.1600, 4.1600)
Urea/BUN, Median (Q1, Q3) 6.3564 (6.3564, 6.3564)
Creatinine, Median (Q1, Q3) 32.7154 (32.7154, 32.7154)
Glucose, Median (Q1, Q3) NA (NA, NA)
Lactate, Median (Q1, Q3) NA (NA, NA)
CRP, Median (Q1, Q3) NA (NA, NA)
Creatine kinase, Median (Q1, Q3) NA (NA, NA)
Variables Lab measures distribution
N Mean Median Min Max Distribution
Baseline visit
Hemoglobin 18.00 13.12 12.80 6.30 18.00
Platelets 18.00 264.94 253.50 71.00 731.00
WCC total 17.00 8.84 6.90 3.00 29.00
Outcomes